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A.I.M.), and Neurology (A.Z.S.), Weill Cornell Medical College, NewYork-Presbyterian Hospital,
New York, New York; and Departments of Radiology and Epidemiology (M.G.M.H.), Erasmus
University Medical Center, Rotterdam, the Netherlands.
Abstract
BACKGROUND AND PURPOSE—Delayed cerebral ischemia and vasospasm are significant
complications following SAH leading to cerebral infarction, functional disability, and death. In
recent years, CTA and CTP have been used to increase the detection of delayed cerebral ischemia
and vasospasm. Our aim was to perform comparative-effectiveness and cost-effectiveness
analyses evaluating CTA and CTP for delayed cerebral ischemia and vasospasm in aneurysmal
SAH from a health care payer perspective.
MATERIALS AND METHODS—We developed a decision model comparing CTA and CTP
with transcranial Doppler sonography for detection of vasospasm and delayed cerebral ischemia in
SAH. The clinical pathways were based on the “Guidelines for the Management of Aneurysmal
Subarachnoid Hemorrhage: A Guideline for Healthcare Professionals from the American Heart
Association/American Stroke Association” (2012). Outcome health states represented mortality
and morbidity according to functional outcomes. Input probabilities of symptoms and serial test
results from CTA and CTP, transcranial Doppler ultrasound, and digital subtraction angiography
were directly derived from an SAH cohort by using a multinomial logistic regression model.
Expected benefits, measured as quality-adjusted life years, and costs, measured in 2012 US
dollars, were calculated for each imaging strategy. Univariable, multivariable, and probabilistic
sensitivity analyses were performed to determine the independent and combined effect of input
parameter uncertainty.
RESULTS—The transcranial Doppler ultrasound strategy yielded 13.62 quality-adjusted life
years at a cost of $154,719. The CTA and CTP strategy generated 13.89 quality-adjusted life years
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at a cost of $147,097, resulting in a gain of 0.27 quality-adjusted life years and cost savings of
$7622 over the transcranial Doppler ultrasound strategy. Univariable and multivariable sensitivity
analyses indicated that results were robust to plausible input parameter uncertainty. Probabilistic
sensitivity analysis results yielded 96.8% of iterations in the right lower quadrant, representing
higher benefits and lower costs.
CONCLUSIONS—Our model results suggest that CTA and CTP are the preferred imaging
strategy in SAH, compared with transcranial Doppler ultrasound, leading to improved clinical
outcomes and lower health care costs.
Aneurysmal SAH is a devastating condition resulting in poor clinical outcomes of patients
who survive long enough to be admitted, with approximately 15% mortality and 58%
functional disability.1 Additionally, as many as 20% of survivors have global cognitive
impairment, also contributing to poor functional status.2 Thus, SAH is associated with a
substantial burden on health care resources, most of which are related to long-term care.3
Despite advances in techniques for aneurysm repair, poor outcomes remain in SAH partly
due to delayed diagnosis and treatment of its secondary complications, mainly vasospasm
and delayed cerebral ischemia (DCI).
Currently, there are several methods available to assist with the diagnosis of vasospasm and
DCI, including clinical examination, neurologic monitoring devices, transcranial Doppler
sonography (TCD), CTA and CTP (CTAP), MR diffusion and perfusion imaging, and
digital subtraction angiography. In clinical practice, patients with SAH are primarily
assessed by clinical examination and TCD, with clinical examination limited because
symptoms are variable and difficult to detect4 and TCD limited by poor sensitivity and
specificity.5-7 At the same time, there are studies reported in the literature that support the
use of CTAP for detection of both vasospasm and perfusion deficits thought to occur in DCI
because of the high sensitivity and specificity of CTAP.8-11 Additionally, emerging data
indicate that perfusion imaging may be more accurate for identification of DCI than
anatomic imaging of arterial narrowing or changes in blood flow velocity by TCD.8,12 Yet,
according to the most recent “Guidelines for the Management of Aneurysmal Subarachnoid
Hemorrhage: A Guideline for Healthcare Professionals from the American Heart
Association/American Stroke Association” (2012),13 both TCD and perfusion imaging with
CT or MR imaging have been assigned the same class IIa recommendation and level B
evidence for detection of vasospasm and DCI. Although CTAP has potential to add
important diagnostic information for guiding management and treatment decisions, there are
no studies to date, to our knowledge, that have assessed the added value of CTAP on clinical
outcomes to fully understand its impact in this patient population. Furthermore, there have
been no randomized trials comparing the impact of different diagnostic methods on patient
outcomes in SAH.
In the past several years, demonstrating the value of imaging has become a major focus in
our changing health care environment. Both quality and safety advocates and third-party
payers have raised concerns regarding medical practice patterns with inappropriate use of
CT, particularly as it relates to radiation exposure. It has become particularly important to
substantiate imaging for specific clinical conditions with scientific evidence to guide
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management and treatment decisions. The purpose of this study was to perform comparative
effectiveness and cost-effectiveness analyses evaluating imaging strategies in SAH for
detection of vasospasm and DCI by using evidence-based guidelines from a health care
payer perspective. Our hypothesis was that CTAP is a cost-effective approach, despite
higher imaging costs, compared with the standard imaging strategy using TCD, resulting in
improved patient outcomes and averted downstream health care costs.
MATERIALS AND METHODS
Model Design
We developed a decision model to perform comparative effectiveness and cost-effectiveness
analyses by using a decision analytic framework in the TreeAge software program (TreeAge
Pro Software, Williamstown, Massachusetts) to compare imaging strategies in SAH from a
health care payer perspective. The detailed model structure is provided in On-line Fig 1.
CTAP was considered the “new imaging strategy” and was compared with TCD as the
“standard imaging strategy.” Clinical examination was included in the model before CTAP
or TCD imaging to assess symptoms of vasospasm and/or DCI, as would typically occur in
the clinical setting. The model was designed to assess patients during the typical time point
at which vasospasm and DCI occur, between 4 and 14 days after SAH.
In the standard strategy, positive concordance between the clinical examination and TCD
results led to induced hypertensive therapy, and negative concordance of the clinical
examination and TCD led to observation, whereas discordance between the clinical
examination and TCD results (such as symptoms but negative TCD findings or no
symptoms but positive TCD findings) led to further testing with DSA. In the new strategy,
CTA and CTP were evaluated as a single examination termed CTAP because these
examinations are typically performed concurrently in clinical practice. If a patient was
symptomatic, a positive CTAP finding was defined as a positive result on either CTA or
CTP, whereas a negative CTAP finding was defined as a negative result on both CTA and
CTP. The rationale is that given the presence of symptoms, a positive result on either
examination provides sufficient supportive evidence to prompt treatment decisions. If a
patient was asymptomatic, a positive CTAP finding was defined as a positive result on both
CTA and CTP, whereas a negative CTAP finding was defined as a negative result on either
CTA or CTP. The rationale is that in the absence of symptoms, a single positive result on
either examination does not provide sufficient evidence to prompt treatment decisions. All
management and treatment decisions are based on the clinical examination and TCD or
CTAP combination tests.
The subsequent management and treatment decisions in the clinical pathway incorporated in
the model were based on the most recent recommendations in the “Guidelines for the
Management of Aneurysmal Subarachnoid Hemorrhage: A Guideline for Healthcare
Professionals from the American Heart Association/ American Stroke Association”
(2012).13 Oral nimodipine was administered to all patients with aneurysmal subarachnoid
hemorrhage (class I recommendation, level A evidence) because it has been shown to
improve neurologic outcomes after SAH. Treatment of DCI is recommended with induction
of hypertension (class I recommendation, level B evidence) and cerebral angioplasty and/or
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selective intra-arterial vasodilator therapy in symptomatic patients, particularly those who
are not rapidly responding to hypertensive therapy (class IIa recommendation, level B
evidence).
Each clinical pathway terminated in an outcome health state reflecting the downstream
morbidity and mortality. A patient was assigned to only 1 of the 3 following health states:
recovered, disability with dependence, or death. The long-term complications of testing or
treatment affecting mortality and morbidity (as defined by the health states) were included in
the model. Short-term complications such as mild allergic reactions were not included
because patients recovered from these temporary ailments; this outcome would not imply
significant reductions in quality of life contributing to these health states.
Input Parameter Probabilities
An outcomes-based approach was used in developing the decision model to directly assess
the effectiveness of CTAP compared with TCD on clinical outcomes instead of primarily
modeling the operating characteristics of these imaging examinations. We modeled
probabilities of test results combined with distributions across clinical outcomes, both
determined conditional on the clinical examination and imaging results. The probabilities
assigned for the occurrence of symptoms and test results of CTAP, TCD, and DSA were
directly derived from an SAH cohort enrolled in a diagnostic accuracy study.10 In this
cohort, patients had both CTAP and TCD performed, which allowed direct comparison of
these imaging strategies in the same patients. According to the study protocol, CTAP was
performed at days 6–8 in asymptomatic patients and the same day that symptoms occurred
in symptomatic patients with clinical deterioration. Day 7 was the median day CTAP was
performed, at which time 45% (44/97) of patients had developed evidence of clinical
deterioration.10 Clinical deterioration may manifest by alterations in consciousness,
worsening on the Glasgow Coma Scale, or new neurologic deficits. For patients with limited
clinical examinations, particularly patients who are comatose or mechanically ventilated,
continuous monitoring of laboratory data and neurologic and systemic parameters was used.
The details of the CTP scanning protocol and postprocessing methods are provided in the
On-line Appendix. TCD was performed daily at the patient's bedside with comparisons
between TCD examinations to evaluate changes in blood flow velocity measurements.
Clinical outcomes of functional disability were also assessed in the same SAH cohort10 and
obtained from medical record review by a neurologist blinded to the hospitalization course
and imaging data. Outcomes were based on the modified Rankin Scale and were categorized
into 3 main health states as recovered (mRS 0–2), disability with dependence (mRS 3–5),
and death (mRS 6). A multinomial prediction model, incorporating conditional dependence
of serial imaging with CTAP and DSA or TCD and DSA, was developed and fitted to
determine the predictive probabilities for each outcome based on the test results and on
being symptomatic or asymptomatic. The 95% simultaneous confidence intervals for
predictive probabilities were computed by using an asymptotic multivariate normal theory
and were based on χ2 tests.14 Statistical analysis was performed with “R: A Language and
Environment for Statistical Computing” (Version 2.13.0; http://www.r-project.org/).15
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Literature sources were used to determine the probabilities of long-term complications from
testing (CTAP and DSA) and/or treatment with induced hypertension and intra-arterial (IA)
therapy. On-line Table 1 demonstrates these input probabilities and their literature sources.
Assessment of Health Benefits and Costs
Health benefits were measured in quality-adjusted life years (QALYs). For each health state,
we assigned a QALY score ranging between 0 and 1.0. Lifetime QALYs were calculated by
multiplying the sum of the number of years spent in each health state by the utility
associated with that state. The life expectancies were estimated from the literature as 28
years for “recovered”16,17 and 10.8 years for “disability.”18,19 The utilities were calculated
as a weighted average from a systematic review of utilities assigned according to mRS
scores.20 The utility of “recovered” (mRS 0–2) was 0.80, and it was 0.22 for “disability”
(mRS 3–5). By convention, “death” (mRS 6) was assigned a value of zero for both life years
and utility.
The economic costs included in the model were those associated with imaging from CTAP,
TCD, and DSA; treatment with induced hypertension and IA-therapy; complications from
imaging and treatment; and disability after SAH, including both short-and long-term care.
The costs for the imaging and treatment were based on the 2012 Medicare reimbursement
rates, including both technical and professional fees. The costs for long-term care for
patients with stroke have been reported in the literature.21 The estimated cost for recovered
patients was calculated as the cumulative annual cost for the expected life years in this
health state. The estimated cost for the disability patients was calculated as the first-year
rehabilitation costs added to the cumulative annual cost for the remaining expected life years
in this health state. By convention, death was assigned no additional cost.
Benefits and costs were discounted at a rate of 3% per year as recommended for cost-
effectiveness analyses in the United States.22,23
Model Validation
Internal validity (sometimes referred to as model verification) examines the extent to which
the model calculations produced expected outcomes based on the data that were used to
derive the model inputs.24 We assessed the internal validity of the model by comparing the
predicted probabilities of the health states (recovered, disability, and death) for each imaging
strategy in the decision model with the observed outcome data from the SAH cohort. The
percentage difference for the model results compared with the observed outcomes was
calculated as a measure of deviation for the probabilities of each health state for the standard
and new imaging strategies separately.
External validity is performed in a similar fashion but uses outcome data that were not used
to develop the model as benchmarks for the predictive performance of the model.24 To
evaluate external validity of the decision model, we compared the overall predicted
probabilities of the health states for both imaging strategies from the decision model with
the published outcome probabilities from the International Subarachnoid Aneurysm Trial
(ISAT).1 The percentage difference was also calculated as a measure of deviation for model
results relative to published outcomes.
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Cost-Effectiveness and Sensitivity Analyses
We calculated the expected benefits and costs associated with each imaging strategy from
the perspective of the health care payer. In the primary analysis for policy decision-making,
the symptomatic and asymptomatic subgroups were combined in each imaging strategy,
weighted by the frequency of symptoms. Additional subgroup analyses were performed to
compare the symptomatic and asymptomatic groups separately. An imaging strategy that
yielded the greatest quality-adjusted life years and lowest costs would be considered the
imaging strategy of choice (dominant strategy).
Sensitivity analyses were performed to test the robustness of the results of the model, given
the uncertainty in the input values for the parameters. One-way sensitivity analyses were
performed for each parameter by altering the input values across the entire range of possible
values (0–1) to identify the key drivers of the model results. In addition, 2-way sensitivity
analyses were performed by simultaneously altering the input values for 2 parameters
together to assess their combined effects on the results of the model. A willingness-to-pay
(WTP) threshold of $100,000 per QALY was used in the 1-way and 2-way sensitivity
analyses.
Probabilistic sensitivity analysis was performed to assess the uncertainty in the model
results, incorporating the uncertainty of all parameter values together. Distributions for the
key model parameters were derived by nonparametric bootstrapping of the SAH cohort,25
focusing attention on the probability of symptoms and the probabilities of imaging (CTAP,
TCD, and DSA) conditional on symptoms. Nonparametric bootstrapping was performed by
resampling analytic datasets with replacement to evaluate the precision around point
estimates without making assumptions regarding the distribution of these variables.26 Pa
rameters that were not directly derived from the cohort (n = 97), such as all other probability
inputs, costs, and utilities, were assigned distributions (such as β, uniform, and α) and varied
on the basis of the SD estimates around the mean values.β distribution is a flexible one,
which is bounded by 0 and 1, which makes it useful for varying probability inputs in
probabilistic sensitivity analysis.26 Uniform distributions assume equal probability of
possible random values between 0 and 1.26 α distributions are rightward skewed with a
lower bound at zero, which makes them useful for varying cost inputs in probabilistic
sensitivity analysis.26 On-line Table 1 demonstrates the input values and distributions used
for all parameters in the model. Results of the probabilistic analysis (10,000 iterations) were
used to generate a cost-effective scatter-plot and cost-effectiveness acceptability curves to
demonstrate the probability that the new strategy is cost-effective for varying cost per
QALY thresholds.
RESULTS
Input Parameter Probabilities
On-line Table 1 demonstrates the probabilities of positive and negative test results for
CTAP, TCD, and DSA in symptomatic and asymptomatic patients calculated directly from
the SAH cohort10 and the predictive probabilities of the outcome health states derived from
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the multinomial prediction model, incorporating serial imaging and clinical data with
conditional dependence.
Model Validation Results
The internal validation revealed that the deviations in the overall probabilities of patients
with good (recovered) and poor (disability and death) outcomes estimated from the decision
model for the new strategy were 1.2% and 3.4%, respectively, relative to the observed data
from the SAH cohort. Within the poor-outcomes group, deviations in the probabilities for
disability and death were 0.9% and 13.7%, respectively. For the standard strategy, the
deviations in the overall probabilities of patients with good and poor outcomes estimated
from the decision model were 5.4% and 16.7%, respectively. Within the poor-outcomes
group, deviations in the probabilities for disability and death were 20% and 3.8%,
respectively.
The external validation revealed that the deviations in the overall probabilities of patients
with good and poor outcomes derived from the decision model were 1.4% and 3.0%,
respectively, compared with the published outcomes data from the ISAT.1 Within the poor-
outcomes group, deviations in the probabilities for disability and death were 55.3% and
62.2%, respectively.
Base Case Analysis
The Table demonstrates the health benefits (QALYs) and costs for the base case scenario
and the subgroup analyses in the symptomatic and asymptomatic patients separately. CTAP
resulted in a gain of health benefits with a cost savings in all analyses, thereby dominating
the standard imaging strategy.
Sensitivity Analysis
Univariable (1-way) sensitivity analyses indicated that the study results were robust to
plausible uncertainty in the parameter values. The CTAP strategy remained preferred
(assuming a WTP of $100,000 per QALY) for all parameters varied over the full range of
possible input values, except for the following: 1) the probability of positive CTAP fell
below 44.2% in symptomatic patients; 2) the probability of complications from induced
hypertension rose above 20.5%; and 3) the probability of recovery with negative CTAP
findings fell below 51.1% in symptomatic and 85.9% in asymptomatic patients.
Multivariable (2-way) sensitivity analyses using the probability of positive CTAP findings
in symptomatic patients and the probability of symptoms revealed that the CTAP strategy is
dominant when the probability of positive CTAP findings in symptomatic patients is >75%
(Fig 1).
The results of the probabilistic sensitivity analysis (10,000 iterations) were used to generate
a cost-effectiveness scatterplot (Fig 2A) and cost-effectiveness acceptability curves (Fig 2B).
The cost-effectiveness scatterplot shows that 96.8% of the iterations in the probabilistic
sensitivity analysis lie in the right lower quadrant, representing higher effectiveness and
lower costs. The cost-effectiveness acceptability curves show that the probability that the
new strategy is cost-effective is consistently high for varying cost per QALY thresholds. At
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the WTP of $50,000 and $100,000 per QALY, the probabilities that the CTAP strategy is
preferred are 98.5% and 98.0%, respectively.
DISCUSSION
Our study reveals that performing CTAP in patients with SAH improves clinical outcomes
compared with TCD, with increased quality of life from less functional disability. Although
CTAP is associated with higher upfront imaging and treatment costs, there are substantial
cost savings associated with this imaging strategy due to overall decreased costs spent on
long-term care for patients with functional disability. Our 1-way and probabilistic sensitivity
analyses assessed a range of costs for CTAP, from $0 to $2000, and revealed that across
these different thresholds, CTAP is still the preferred strategy compared with TCD. CTAP
represents a dominant strategy because it provides both better health outcomes and lower
costs in the overall patient population and in the symptomatic and asymptomatic subgroups
separately. These results support the implementation of CTAP in all SAH, including both
symptomatic and asymptomatic patients. Furthermore, our study demonstrates that changing
the WTP threshold from $50,000 to $100,000 does not significantly change the model
results. The cost-effective acceptability curves generated from the probabilistic sensitivity
analysis are helpful in visualizing the effect that a change in WTP can have on these results
(Fig 2). CTAP remains the preferred imaging strategy across the entire range of commonly
used WTP thresholds in the United States.27
In this cost-effectiveness analysis, an outcomes-based approach was used to directly assess
the effectiveness of CTAP compared with TCD on clinical outcomes. Most decision
analyses for diagnostic tests model the underlying diagnostic truth in combination with the
sensitivity and specificity of the test.27 Here we modeled probabilities of test results
combined with distributions across clinical outcomes, both determined conditional on the
clinical examination and previous test results. We chose this alternative approach because of
controversy about the appropriate reference standard test for DCI and lack of diagnostic
performance data of these tests. Because all conditional probabilities of test results and
distributions across clinical outcomes were derived from one and the same well-documented
cohort of patients with SAH,10 this alternative modeling approach ensures internal
consistency of the model. We are confident that the model structure accurately reflects SAH
disease pathways because the model results matched the health states (good and poor
outcomes) compared with the SAH cohort and ISAT populations in our internal and external
model validation analyses. Additionally, the sensitivity analyses demonstrated that the
model results were robust to variations in the input values for all parameters.
There are several limitations of our study. First, we modeled health outcomes conditional on
diagnostic tests performed in a single cohort, calling into question the generalizability of the
model. This approach had the advantage of direct comparison of CTAP and TCD in the
same patients, and ensured internal consistency of the data. Even though the external
validation of the model revealed that the proportion of patients with good (recovered) and
poor (disability and death) outcomes were similar to those in the ISAT,1 greater variation
was seen within the poor-outcomes group. The ISAT reported higher mortality compared
with the decision model; this would be expected because the older data presented in the
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ISAT (1994–2002) do not adequately reflect the currently improved mortality rates due to
more aggressive management of complications related to SAH such as hydrocephalus,
vasospasm, and DCI.13 Additionally, the ISAT reported a 5-year mortality rate rather than
the mortality rate within the hospitalization period that we report, which likely also
contributed to its higher mortality compared with the decision model because some of our
patients may experience delayed mortality due to stroke complications. Furthermore,
deviation in the internal validation results was also seen in the poor-outcomes group with the
model predicting higher disability and death compared with the SAH cohort. This deviation
in the results may be partly attributed to the real-world variation in clinical decision making
observed in the SAH cohort compared with the decision model, in which standardized
management and treatment decisions were based strictly on the clinical examination and
imaging results. Second, the potential long-term effects from low-level radiation exposure
used in medical imaging, such as cancer induction, were not included in the model because
cancer risks at low doses are very uncertain in the adult population and depend on limited
data extrapolating risks from atomic bomb survivors who were exposed to high doses.28
Currently, there are no data available on the lifetime cancer risk from CTAP imaging
according to patient age at exposure, sex, and reduced life expectancy from underlying
disease, particularly aneurysmal subarachnoid hemorrhage, delayed cerebral ischemia,
and/or vasospasm. Because our model was designed to specifically assess patients during the
typical time point of DCI and vasospasm between days 4 and 14 after SAH, we only
included the morbidity and mortality during the hospitalization period and at discharge.
Last, the possible added benefits of performing serial TCD examinations at the bedside to
improve detection of vasospasm by monitoring temporal changes in blood-velocity
measurements and avoiding intrahospital transportation were not included in the decision
analysis because of the lack of estimates in the literature to accurately incorporate them in
the model.
CONCLUSIONS
In summary, our results have important implications in clinical practice in managing patients
with SAH. Our model suggests that CTAP is the preferred initial imaging strategy compared
with TCD because it results in both improved clinical outcomes and lower health care costs.
Furthermore, the results of this study provide supportive evidence for the widespread
implementation of CTAP in both symptomatic and asymptomatic patients. In the current
economic environment aimed at improving health care quality and reducing costs, imaging
patients with SAH with CTAP should achieve both aims.
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FIG 1.
Multivariable (2-way) sensitivity analysis graph demonstrating how the decision depends on
the values of the probability of positive findings on a CTA and CTP examination in
symptomatic patients (Sx) and the probability of symptoms in the SAH population across all
ranges. The new strategy represents CTAP imaging, and the standard strategy represents
TCD imaging.
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FIG 2.
Probabilistic sensitivity analysis scatterplot (A) and cost-effectiveness acceptability curves
(B) comparing the new strategy versus the standard strategy. The new strategy represents
CTAP imaging and the standard strategy represents TCD imaging.
Sanelli et al. Page 14
AJNR Am J Neuroradiol. Author manuscript; available in PMC 2015 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Sanelli et al. Page 15
Health benefits (QALYs) and costs for the base case scenario and subgroup analyses in symptomatic and
asymptomatic patients
Imaging Strategy QALYs Cost
Base case scenario:
    CTAP 13.89 $147,097
    TCD 13.62 $154,719
    Difference (CTAP-TCD) +0.27 –$7,622
Symptomatic subgroup:
    CTAP 13.75 $149,382
    TCD 13.74 $152,820
    Difference (CTAP-TCD) +0.01 – $3,438
Asymptomatic subgroup:
    CTAP 13.99 $145,228
    TCD 13.51 $156,272
    Difference (CTAP-TCD) +0.48 – $11,044
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